The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
Location: REDI (East Bay)Please contact Asha Damunugahakubura DamunuA@sutterhealth.org about study ERC 242 View study details on ClinicalTrials.gov
Please note that trial statuses change frequently. For the most up-to-date information, please contact the Research Department at 510.204.4155.
March 15, 2018
Breast Tumor and Blood markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Investigator: Sandra Wilson, Ph.D.
Primary and Secondary Prevention of Osteoporosis-Related Fracture: The Use of DEXA and FRAX Results in a Community–based Practice
Investigator: Harold (Hal) Luft, Ph.D.